Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes
Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin
Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes
27 August 2021
ESC Premium Access
SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis
27 August 2021
ESC Premium Access
Impact of COVID-19 pandemics upon pulmonary hypertension patients: insights from BNP-PL national database